Fabentech is launching the production of its treatment against Ebola
Fabentech, specialising in the treatment of emerging infectious diseases for 5 years, is offering passive anti-infective immunotherapy solutions based on specific and highly-purified polyclonal antibodies.
Recognised for its production capacities, its short development lead times and the quality of its products, Fabentech has accelerated its project to develop a treatment against Ebola, in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).
These highly-purified antibodies for use in humans aim to specifically and immediately neutralise the virus and to slow down disease progression, alongside the vaccination and antiviral strategies under development.
Invited last week to the inauguration of the first BSL-4 high-containment laboratory in Wuhan, China, in the presence of Official Representatives of the French delegation, and to the associated Ebola symposium, Dr Bertrand Lépine, Chairman of the Management Board of Fabentech, confirmed his commitment to the fight against Ebola: “Today, we are launching the production of our anti-Ebola treatment and we expect it to be available in the summer of 2015, as part of clinical development or compassionate use.”
Fabentech is thus participating in the international mobilisation launched in response to the unprecedented epidemic in West Africa. The Fabentech product will therefore be ready to respond to any Ebola-related health emergency.
Fabentech bases the development and production of its products on a platform established from a licence of the Sanofi Pasteur’s technology, complemented by collaboration and subcontracting contracts.
